Cargando…

Antibody persistence after a single dose of quadrivalent HPV vaccine and the effect of a dose of nonavalent vaccine given 3-8 years later – an exploratory study

The objective of this study was to assess the persistence of antibodies after a single dose of quadrivalent HPV vaccine (4vHPV) and the effect of a dose of nonavalent HPV vaccine (9vHPV) given 3–8 years later. Such data might be of interest in the decision-making process regarding the 2-dose course...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gilca, Vladimir, Sauvageau, Chantal, Panicker, Gitika, De Serres, Gaston, Ouakki, Manale, Unger, Elizabeth R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2018
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422519/ https://www.ncbi.nlm.nih.gov/pubmed/30252583 http://dx.doi.org/10.1080/21645515.2018.1522469

Ejemplares similares

Cost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

Single-dose nonavalent HPV vaccine: Need of the hour
por: Pal, Manidip, et al.
Publicado: (2020)

Delayed dosing intervals for quadrivalent human papillomavirus vaccine do not reduce antibody avidity
por: Brady, Allison M., et al.
Publicado: (2020)

Human Papilloma Virus vaccine and cervical cancer screening acceptability among adults in Quebec, Canada
por: Sauvageau, Chantal, et al.
Publicado: (2007)

Impact of vaccine delays at the 2, 4, 6 and 12 month visits on incomplete vaccination status by 24 months of age in Quebec, Canada
por: Kiely, Marilou, et al.
Publicado: (2018)

Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination
por: Joshi, Smita, et al.
Publicado: (2023)

BNT162b2 Effectiveness Against Delta and Omicron Variants of Severe Acute Respiratory Syndrome Coronavirus 2 in Adolescents Aged 12–17 Years, by Dosing Interval and Duration
por: Ionescu, Iulia G, et al.
Publicado: (2023)

Early use of the HPV 2-dose vaccination schedule: Leveraging evidence to support policy for accelerated impact
por: Gilca, Vladimir, et al.
Publicado: (2018)

Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA–Vaccinated and Nonvaccinated Individuals in Quebec, Canada
por: Carazo, Sara, et al.
Publicado: (2022)

Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study
por: Carazo, Sara, et al.
Publicado: (2023)

Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France
por: Riethmuller, Didier, et al.
Publicado: (2015)

Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine
por: Petry, Karl-Ulrich, et al.
Publicado: (2018)

Canadian family physicians' and paediatricians' knowledge, attitudes and practices regarding A(H1N1) pandemic vaccine
por: Dubé, Eve, et al.
Publicado: (2010)

Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain
por: De La Fuente, Jesús, et al.
Publicado: (2019)

Sensitivity of Human Papillomavirus (HPV) Lineage and Sublineage Variant Pseudoviruses to Neutralization by Nonavalent Vaccine Antibodies
por: Godi, Anna, et al.
Publicado: (2019)

Potential impact of a nonavalent anti HPV vaccine in Italian men with and without clinical manifestations
por: Bosco, Liana, et al.
Publicado: (2021)

Feasibility and impact of providing feedback to vaccinating medical clinics: evaluating a public health intervention
por: Brousseau, Nicholas, et al.
Publicado: (2010)

Immunogenicity of 2 and 3 Doses of the Quadrivalent Human Papillomavirus Vaccine up to 120 Months Postvaccination: Follow-up of a Randomized Clinical Trial
por: Donken, Robine, et al.
Publicado: (2020)

Cellular Immune Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent HPV Vaccine in Fijian Girls and Subsequent Responses to a Dose of Bivalent HPV Vaccine
por: Toh, Zheng Quan, et al.
Publicado: (2018)

Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate
por: Nham, Eliel, et al.
Publicado: (2023)

Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada
por: Skowronski, Danuta M, et al.
Publicado: (2022)

The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
por: Patel, Cyra, et al.
Publicado: (2018)

Ongoing inadequacy of quadrivalent HPV vaccine safety studies
por: Little, Deirdre T, et al.
Publicado: (2020)

1168. Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate
por: Nham, Eliel, et al.
Publicado: (2023)

A single dose of quadrivalent human papillomavirus (HPV) vaccine is immunogenic and reduces HPV detection rates in young women in Mongolia, six years after vaccination
por: Batmunkh, Tsetsegsaihan, et al.
Publicado: (2020)

An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population
por: Fochesato, Anna, et al.
Publicado: (2022)

Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study
por: Sankaranarayanan, Rengaswamy, et al.
Publicado: (2016)

926. Antibody Response to HPV Vaccination in Pediatric and Adolescent People Living with HIV (PLWH)
por: Al Hammoud, Roukaya, et al.
Publicado: (2020)

Fraction of high-grade cervical intraepithelial lesions attributable to genotypes targeted by a nonavalent HPV vaccine in Galicia, Spain
por: Perez, S., et al.
Publicado: (2017)

Age-Related Changes in the Fraction of Cervical Intraepithelial Neoplasia Grade 3 Related to HPV Genotypes Included in the Nonavalent Vaccine
por: Giannella, Luca, et al.
Publicado: (2019)

Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain
por: Ruiz-Aragón, Jesús, et al.
Publicado: (2022)

Cost-effectiveness for high dose quadrivalent versus the adjuvanted quadrivalent influenza vaccine in the Italian older adult population
por: Rumi, Filippo, et al.
Publicado: (2023)

Effectiveness of quadrivalent HPV vaccination in reducing vaccine-type and nonvaccine-type high risk HPV infection
por: Li, Chenxi, et al.
Publicado: (2023)

Nonavalent human papillomavirus vaccination as a treatment for warts in an immunosuppressed adult
por: Ferguson, Sara B., et al.
Publicado: (2017)

Correction to: Fraction of high-grade cervical intraepithelial lesions attributable to genotypes targeted by a nonavalent HPV vaccine in Galicia, Spain
por: Perez, S., et al.
Publicado: (2018)

Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States
por: Gee, Julianne, et al.
Publicado: (2016)

Increases in HPV-16/18 antibody avidity and HPV-specific memory B-cell response in mid-adult aged men post-dose three of the quadrivalent HPV vaccine
por: Miller, Cheryl N., et al.
Publicado: (2021)

Immunological response to quadrivalent HPV vaccine in treatment of recurrent respiratory papillomatosis
por: Tjon Pian Gi, Robin E. A., et al.
Publicado: (2016)

Modelling the effects of quadrivalent Human Papillomavirus (HPV) vaccination in Puerto Rico
por: Ortiz, Ana Patricia, et al.
Publicado: (2017)

Measles in Canada Between 2002 and 2013
por: De Serres, Gaston, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ns9vvqvnsrlr33tkuaiks00772